Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Innoviva Inc (INVA) Common Stock USD0.01

Sell:$11.18 Buy:$11.19 Change: $0.07 (0.62%)
NASDAQ:1.71%
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
Sell:$11.18
Buy:$11.19
Change: $0.07 (0.62%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
Sell:$11.18
Buy:$11.19
Change: $0.07 (0.62%)
Market closed |  Prices as at close on 22 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

Contact details

Address:
2000 Sierra Point Pkwy Ste 500
BRISBANE
94005-1830
United States
Telephone:
+1 (650) 2389600
Website:
https://www.inva.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
INVA
ISIN:
US45781M1018
Market cap:
$1.17 billion
Shares in issue:
101.39 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Odysseas Kostas
    Independent Chairman of the Board
  • Pavel Raifeld
    Chief Executive Officer
  • Marianne Zhen
    Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.